Abstract:Cancer immunotherapy harness the body’s immune system to eliminate cancer, by using a broad panel of soluble and membrane proteins as therapeutic targets. Immunosuppression signaling mediated by ligand-receptor interaction may be blocked by monoclonal antibodies, but because of repopulation of the membrane via intracellular organelles, targets must be eliminated in whole cells. Targeted protein degradation, as exemplified in proteolysis targeting chimera (PROTAC) studies, is a promising strategy for selective inhibition of target proteins. The recently reported use of lysosomal targeting molecules to eliminate immune checkpoint proteins has paved the way for targeted degradation of membrane proteins as crucial anti-cancer targets. Further studies on these molecules’ modes of action, target-binding “warheads”, lysosomal sorting signals, and linker design should facilitate their rational design. Modifications and derivatives may improve their cell-penetrating ability and the in vivo stability of these pro-drugs. These studies suggest the promise of alternative strategies for cancer immunotherapy, with the aim of achieving more potent and durable suppression of tumor growth. Here, the successes and limitations of antibody inhibitors in cancer immunotherapy, as well as research progress on PROTAC- and lysosomal-dependent degradation of target proteins, are reviewed.

Structure-Activity Relationships of Noncovalent Immunoproteasome 5I-Selective Dipeptides

Identification of N, C-capped Di- and Tripeptides As Selective Immunoproteasome Inhibitors

Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

Development of peptide epoxyketones as selective immunoproteasome inhibitors

Design, Synthesis and Biological Evaluation of Novel Tripeptidyl Epoxyketone Derivatives Constructed from Β-Amino Acid As Proteasome Inhibitors.

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

Design, Synthesis and Biological Evaluation of Dipeptides As Novel Non-Covalent 20S Proteasome Inhibitors

Discovery of novel non-covalent inhibitors selective to the β5-subunit of the human 20S proteasome

Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.

Non-peptidic Immunoproteasome Β5i-Selective Inhibitor As Potential Treatment for Idiopathic Pulmonary Fibrosis: Virtual Screening, Hit Evolution and Lead Identification.

Exploration of Novel Macrocyclic Dipeptide N-benzyl Amides As Proteasome Inhibitors.

Design and Synthesis of Tripeptidyl Furylketones As Selective Inhibitors Against the Β5 Subunit of Human 20S Proteasome

A Computer Screening Approach to Immunoglobulin Superfamily Structures and Interactions: Discovery of Small Non-Peptidic CD4 Inhibitors As Novel Immunotherapeutics.

Synthesis and Application of a Versatile Immunoproteasome Activity Probe

Design, Synthesis and Biological Evaluation of Triaryl Compounds As Novel 20S Proteasome Inhibitors.

Bioactive Peptide Design Based on Protein Surface Epitopes: A CYCLIC HEPTAPEPTIDE MIMICS CD4 DOMAIN 1 CC′ LOOP AND INHIBITS CD4 BIOLOGICAL FUNCTION

Synthesis, Bioactivity, Docking and Molecular Dynamics Studies of Furan‐Based Peptides As 20S Proteasome Inhibitors

Preparation and Biological Evaluation of Soluble Tetrapeptide Epoxyketone Proteasome Inhibitors.

Optimization of Peptidomimetics as Selective Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction.

Proteasomal and Lysosomal Degradation for Specific and Durable Suppression of Immunotherapeutic Targets